267 related articles for article (PubMed ID: 19688297)
1. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Dresemann G; Weller M; Rosenthal MA; Wedding U; Wagner W; Engel E; Heinrich B; Mayer-Steinacker R; Karup-Hansen A; Fluge O; Nowak A; Mehdorn M; Schleyer E; Krex D; Olver IN; Steinbach JP; Hosius C; Sieder C; Sorenson G; Parker R; Nikolova Z
J Neurooncol; 2010 Feb; 96(3):393-402. PubMed ID: 19688297
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Gururangan S; Peters KB; McLendon R; Sathornsumetee S; Rich JN; Lipp ES; Janney D; Friedman HS
Cancer; 2012 Oct; 118(19):4759-67. PubMed ID: 22371319
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide for high grade glioma.
Hart MG; Garside R; Rogers G; Stein K; Grant R
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
[TBL] [Abstract][Full Text] [Related]
5. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
[TBL] [Abstract][Full Text] [Related]
6. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
7. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
Dresemann G
Ann Oncol; 2005 Oct; 16(10):1702-8. PubMed ID: 16033874
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Yung WK; Albright RE; Olson J; Fredericks R; Fink K; Prados MD; Brada M; Spence A; Hohl RJ; Shapiro W; Glantz M; Greenberg H; Selker RG; Vick NA; Rampling R; Friedman H; Phillips P; Bruner J; Yue N; Osoba D; Zaknoen S; Levin VA
Br J Cancer; 2000 Sep; 83(5):588-93. PubMed ID: 10944597
[TBL] [Abstract][Full Text] [Related]
10. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
12. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Wang Y; Kong X; Guo Y; Wang R; Ma W
Medicine (Baltimore); 2017 Mar; 96(10):e6261. PubMed ID: 28272232
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; Mohile N; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M
J Neurooncol; 2016 Jan; 126(2):309-16. PubMed ID: 26508094
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
16. Rechallenge with temozolomide in patients with recurrent gliomas.
Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
[TBL] [Abstract][Full Text] [Related]
18. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Boiardi A; Silvani A; Eoli M; Lamperti E; Salmaggi A; Gaviani P; Fiumani A; Botturi A; Falcone C; Solari A; Filippini G; Di Meco F; Broggi G
J Neurooncol; 2008 May; 88(1):105-13. PubMed ID: 18283418
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Conti A; Pontoriero A; Arpa D; Siragusa C; Tomasello C; Romanelli P; Cardali S; Granata F; De Renzis C; Tomasello F
Acta Neurochir (Wien); 2012 Feb; 154(2):203-9. PubMed ID: 21984132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]